FIRST AIRED: June 25, 2019

Nice work! Enjoy the show!

×

You’re busy. We get it.

Stay on top of the news with our Editor’s Picks newsletter.

US Edition
Intl. Edition
Unsubscribe at any time. One click, it’s gone.

Thanks for signing up!

We've got more news

Get our editor’s daily email summary of what’s going on in the world.

US Edition
Intl. Edition
Replay Program
0:00
0:00
More Info

COMING UP:Share Opener Variant 3

×

Transcript

00:00:00
once jilted at the altar by Fizer botox maker eller again is sitting pretty Monday in a huge deal at V. is buying out again for about sixty three billion dollars to one hundred eighty eight dollars twenty four cents per share offer is forty five percent higher than allergens closing price Monday Abby makes a blockbuster arthritis drug Q. Mereb you seeking to diversify its line up because you mera face competition from cheaper versions in Europe allergen once a Darling for botox dry I drug wrist asus and other beauty treatments has been under pressure analysts expect the company to break itself up it sure is it lost half their value following Fizer decision to walk away from its acquisition deal three years ago Fraser's offer was two and a half times bigger than Abby's current bid have the analogy and said the deal will boost is adjusted earnings per share by ten percent in the first year following the close out again sure shot up twenty nine percent at the start of trading Tuesday Abby shares fell eleven percent